Table 4.
Prognostic role of NER pathway mRNA expression in CRC.
| Gene | Subgroup | Colon cancer | Rectal cancer | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||||
| HR (95% CI) | P | Adjusted HR (95% CI) | P | HR (95% CI) | P | Adjusted HR (95% CI) | P | ||
| ERCC1 | 1.30 (0.88–1.93) | 0.192 | 1.27 (0.84–1.90) | 0.256 | 1.23 (0.57–2.65) | 0.606 | 0.97 (0.40–2.34) | 0.951 | |
| ERCC2 | 1.35 (0.91–2.00) | 0.142 | 1.53 (1.01–2.31) | 0.043 | 1.26 (0.58–2.73) | 0.559 | 2.48 (0.90–6.82) | 0.078 | |
| Male | 1.84 (1.04–3.26) | 0.037 | |||||||
| Female | 1.22 (0.66–2.24) | 0.532 | |||||||
| ERCC3 | 1.16 (0.79–1.71) | 0.459 | 0.89 (0.60–1.34) | 0.587 | 1.07 (0.49–2.35) | 0.870 | 1.49 (0.59–3.77) | 0.404 | |
| ERCC4 | 0.76 (0.51–1.12) | 0.166 | 0.74 (0.49–1.11) | 0.148 | 0.52 (0.23–1.14) | 0.101 | 0.70 (0.28–1.76) | 0.452 | |
| Male | 0.54 (0.30–0.96) | 0.035 | |||||||
| Female | 1.15 (0.63–2.09) | 0.654 | |||||||
| ERCC5 | 1.16 (0.79–1.72) | 0.449 | 0.95 (0.63–1.42) | 0.784 | 0.82 (0.38–1.78) | 0.613 | 0.64 (0.26–1.56) | 0.328 | |
| ERCC6 | 1.11 (0.76–1.64) | 0.592 | 1.24 (0.83–1.84) | 0.302 | 1.38 (0.63–3.02) | 0.415 | 1.16 (0.48–2.80) | 0.745 | |
| ERCC8 | 0.95 (0.64–1.39) | 0.780 | 1.01 (0.67–1.52) | 0.964 | 0.95 (0.44–2.07) | 0.905 | 1.75 (0.71–4.34) | 0.224 | |
| XPA | 1.19 (0.80–1.77) | 0.398 | 1.13 (0.75–1.71) | 0.552 | 1.24 (0.56–2.74) | 0.591 | 0.98 (0.36–2.68) | 0.971 | |
| XPC | 0.85 (0.58–1.25) | 0.407 | 0.75 (0.50–1.12) | 0.159 | 0.40 (0.18–0.89) | 0.026 | 0.55 (0.21–1.42) | 0.214 | |
| Male | 0.26 (0.08–0.88) | 0.030 | |||||||
| Female | 0.61 (0.20–1.87) | 0.385 | |||||||
| DDB1 | 0.73 (0.50–1.08) | 0.118 | 0.87 (0.58–1.30) | 0.488 | 0.62 (0.28–1.39) | 0.242 | 0.90 (0.37–2.19) | 0.811 | |
| DDB2 | 1.03 (0.70–1.52) | 0.882 | 1.27 (0.84–1.92) | 0.262 | 1.32 (0.61–2.86) | 0.482 | 1.24 (0.51–2.99) | 0.636 | |